Proteomic analysis of doxorubicin-induced changes in the proteome of HepG2cells combining 2-D DIGE and LC-MS/MS approaches

Proteomics

Volumn 10, Issue 1, 2010, Pages 99-114

  Hammer, Elke ^a   Bien, Sandra ^a   Salazar, Manuela Gesell ^a   Steil, Leif ^a   Scharf, Christian ^a   Hildebrandt, Petra ^a   Schroeder, Henry W S ^a   Kroemer, Heyo K ^a   Völker, Uwe ^a   Ritter, Christoph A ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

1 D electrophoresis in combination with LC MS MS; 2 D DIGE; Cell biology; Differential protein expression; Doxorubicin induced toxicity; Stable isotope labeling

Indexed keywords

AMINO ACID; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; DNA; DOXORUBICIN; STABLE ISOTOPE; STRUCTURAL PROTEIN;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CELL CULTURE; CELL CYCLE; CELL STRAIN HEPG2; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DATA ANALYSIS; DNA DAMAGE; DNA REPLICATION; ELECTRON TRANSPORT; ELECTROSPRAY MASS SPECTROMETRY; FUNCTIONAL PROTEOMICS; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

CELL SURVIVAL; CHROMATOGRAPHY, LIQUID; DNA; DNA DAMAGE; DNA REPLICATION; DOXORUBICIN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HEP G2 CELLS; HUMANS; PROTEIN BIOSYNTHESIS; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 73549095180     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800626     Document Type: Article

References (44)

1. Di Marco, A., Gaetani, M., Scarpinato, B., Adriamycin (NSC-123, 127): a new antibiotic with antitumor activity. Cancer Chemother. Rep. 1969, 53, 33-37.
2. Gewirtz, D. A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57, 727-741.
3. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229.
4. Friesen, C., Herr, I., Krammer, P. H., Debatin, K. M., Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 1996, 2, 574-577.
5. Green, P. S., Leeuwenburgh, C., Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim. Biophys. Acta 2002, 1588, 94-101.
6. 2-and p53-dependent pathways. J. Biol. Chem. 2004, 279, 25535-25543.
7. Burns, C. P., North, J. A., Petersen, E. S., Ingraham, L. M., Subcellular distribution of doxorubicin: comparison of fatty acid-modified and unmodified cells. Proc. Soc. Exp. Biol. Med. 1988, 188, 455-460.
8. Chen, Y., Walsh, R. J., Arriaga, E. A., Selective determination of the doxorubicin content of individual acidic organelles in impure subcellular fractions. Anal. Chem. 2005, 77, 2281-2287.
9. Lebrecht, D., Kokkori, A., Ketelsen, U. P., Setzer, B., Walker, U. A., Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J. Pathol. 2005, 207, 436-444.
10. Solaini, G., Ronca, G., Bertelli, A., Inhibitory effects of several anthracyclines on mitochondrial respiration and coenzyme Q10 protection. Drugs Exp. Clin. Res. 1985, 11, 533-537.
11. Solem, L. E., Henry, T. R., Wallace, K. B., Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 1994, 129, 214-222.
12. Rebbaa, A., Chou, P.M., Emran, M.,Mirkin, B. L., Doxorubicin-induced apoptosis in caspase-8-deficient neuroblastoma cells is mediated through direct action on mitochondria. Cancer Chemother. Pharmacol. 2001, 48, 423-428.
13. Bien, S., Ritter, C. A., Gratz,M., Sperker, B. et al., Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Mol. Pharmacol. 2004, 65, 1092-1102.
14. Singal, P. K., Segstro, R. J., Singh, R. P., Kutryk, M. J., Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can. J. Cardiol. 1985, 1, 139-147.
15. Wang, J., Chan, J. Y., Fong, C. C., Tzang, C. H. et al., Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines. Liver Int. 2009, 29, 1338-1347.
16. [3H]thymidine incorporation assay. J. Immunol. Methods 1994, 170, 211-224.
17. Thiele, T., Steil, L., Gebhard, S., Scharf, C. et al., Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion 2007, 47, 1221-1233.
18. Olsen, J. V., Ong, S. E., Mann, M., Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol. Cell. Proteomics 2004, 3, 608-614.
19. Lee, T. K., Lau, T. C., Ng, I. O., Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother. Pharmacol. 2002, 49, 78-86.
20. Moriyama, M., Hoshida, Y., Otsuka, M., Nishimura, S. et al., Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol. Cancer Ther. 2003, 2, 199-205.
21. Hong, Y., Muller, U. R., Lai, F., Discriminating two classes of toxicants through expression analysis of HepG2 cells with DNA arrays. Toxicol. In Vitro 2003, 17, 85-92.
22. Pang, R. T. K., Poon, T. C. W., Wong, N., Lai, P. B. S. et al., Comparison of protein expression patterns between hepatocellular carcinoma cell lines and a hepatoblastoma cell line. Clin. Proteomics J. 2004, 1, 313-331.
23. Lu, G. D., Shen, H.-M., Ong, C. N., Chung, M. C. M., Anticancer effects of aloe-emodin on HepG2 cells: Cellular and proteomic studies. Proteomics Clin. Appl. 2007, 1, 410-419.
24. Zhang, Y., Fan, X. G., Chen, R., Xiao, Z. Q. et al., Comparative proteome analysis of untreated and Helicobacter pylori-treated HepG2. World J. Gastroenterol. 2005, 11, 3485-3489.
25. Lee, C. L., Hsiao, H. H., Lin, C. W., Wu, S. P. et al., Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics 2003, 3, 2472-2486.
26. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
27. Kudoh, K., Ramanna, M., Ravatn, R., Elkahloun, A. G. et al., Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 2000, 60, 4161-4166.
28. Fritzsche, H., Wahnert, U., Chaires, J. B., Dattagupta, N. et al., Anthracycline antibiotics. Interaction with DNA and nucleosomes and inhibition of DNA synthesis. Biochem. 1987, 26, 1996-2000.
29. Taatjes, D. J., Fenick, D. J., Gaudiano, G., Koch, T. H., A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancer. Curr. Pharm. Design 1998, 4, 203-218.
30. Lawrence, T. S., Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells. Cancer Res. 1988, 48, 725-730.
31. Belloni, M., Uberti, D., Rizzini, C., Jiricny, J., Memo, M., Induction of two DNA mismatch repair proteins, MSH2 and MSH6, in differentiated human neuroblastoma SH-SY5Y cells exposed to doxorubicin. J. Neurochem. 1999, 72, 974-979.
32. 18O labeling. J. Proteome Res. 2004, 3, 455-462.
33. Chen, S. T., Pan, T. L., Tsai, Y. C., Huang, C. M., Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett. 2002, 181, 95-107.
34. Ku, N. O., Liao, J., Chou, C. F., Omary, M. B., Implications of intermediate filament protein phosphorylation. Cancer Metastasis Rev. 1996, 15, 429-444.
35. Anderson, J. M., Heindl, L. M., Bauman, P. A., Ludi, C. W. et al., Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents. Clin. Cancer Res. 1996, 2, 97-105.
36. Smith, L., Watson, M. B., O'Kane, S. L., Drew, P. J. et al., The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer Ther. 2006, 5, 2115-2120.
37. Bambang, I. F., Lu, D., Li, H., Chiu, H.-H. et al., Cytokeratin 19 regulates endoplasmic reticulum stress and inhibits ERp29 expression via p38 MAPK/XBP-1 signaling in breast cancer cells. Exp. Cell Res. 2009, 315, 1964-1974.
38. Gilbert, S., Loranger, A., Daigle, N., Marceau, N., Simple epithelial keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J. Cell Biol. 2001, 154, 763-773.
39. Yang, X. R., Xu, Y., Shi, G. M., Fan, J. et al., Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin. Cancer Res. 2008, 14, 3850-3859.
40. Shaw, R. J., Henry, M., Solomon, F., Jacks, T., RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol. Biol. Cell 1998, 9, 403-419.
41. Simons, P. C., Pietromonaco, S. F., Reczek, D., Bretscher, A. et al., C-terminal threonine phosphorylation activates ERM proteins to link the cell's cortical lipid bilayer to the cytoskeleton. Biochem. Biophys. Res. Commun. 1998, 253, 561-565.
42. Niggli, V., Rossy, J., Ezrin/radixin/moesin: versatile controllers of signaling molecules and of the cortical cytoskeleton. Int. J. Biochem. Cell. Biol. 2008, 40, 344-349.
43. Omary, M. B., Baxter, G. T., Chou, C. F., Riopel, C. L. et al., PKC epsilon-related kinase associates with and phosphorylates cytokeratin 8 and 18. J. Cell. Biol. 1992, 117, 583-593.
44. Gambetta, R. A., Banfi, P., Lanzi, C., Franzi, A. et al., Protein kinase C activation and lipid peroxidation by doxorubicin analogues. Tumori 1989, 75, 358-361.